Earnings ·
Jaguar Health reported second-quarter 2026 financial results showing a net loss of $12.7 million, or $15.68 per share…
JAGXJaguar Health, Inc.
Jaguar Health reported second-quarter 2026 financial results showing a net loss of $12.7 million, or $15.68 per share, compared to a $10.4 million loss in the prior year period. Total revenue decreased 59% to $1.2 million, driven by a 60% drop in prescription product sales as commercial rights for Mytesi and Canalevia-CA1 were licensed to Future Pak. The company recognized $43,000 in license fees from a European partner and received the final $2 million holdback payment under its U.S. licensing agreement with Future Pak. Operating expenses decreased by approximately $2.1 million due to the dissolution of the Jaguar/Napo sales group, though R&D costs rose slightly to support crofelemer powder formulation development for rare intestinal failure diseases. The company expects to submit a New Drug Application for microvillus inclusion disease in Q2 2027. Jaguar Health develops novel prescription drugs derived from plants for gastrointestinal disorders.